How Clear.bio saved €𝟭.𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗮𝘃𝗼𝗶𝗱𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗰𝗼𝘀𝘁𝘀

Imagine knowing exactly how your body responds to what you eat. For 1.2 million people in the Netherlands living with type 2 diabetes, that kind of insight changes everything. That is exactly what our portfolio company Clear.bio delivers. 🙌

Clear.bio monitors blood glucose via a sensor while patients log their food intake. The platform connects them with dietitians and gives care providers real-time data insights. No more guesswork. No more waiting months for a check-up to find out if anything has changed. After just 12 weeks, 62% of users spend more time in a healthy glucose range, and 25% use less or no medication at all.

𝗜𝗻 𝟮𝟬𝟮𝟱, 𝘁𝗵𝗮𝘁 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗲𝗱 𝗶𝗻𝘁𝗼 €𝟭.𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗮𝘃𝗼𝗶𝗱𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗰𝗼𝘀𝘁𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝟭,𝟭𝟱𝟲 𝗮𝗰𝘁𝗶𝘃𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝘄𝗶𝘁𝗵 𝗮 𝟵𝟯% 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗿𝗮𝘁𝗶𝗻𝗴.

For someone who has been managing a chronic condition for years, that is life-changing.  Better outcomes for patients, lower costs for the system. That is what investing in the right solutions looks like. And Clear.bio is not the only one in our portfolio making a difference.

Our Impact in Progress 2025 report covers ten companies in full. 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘁𝗵𝗲𝘆 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗲𝗱 €𝟴𝟴.𝟯 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗮𝘃𝗼𝗶𝗱𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗮𝗻𝗱 𝘀𝗼𝗰𝗶𝗲𝘁𝗮𝗹 𝗰𝗼𝘀𝘁𝘀 𝗶𝗻 𝟮𝟬𝟮𝟱 𝗮𝗻𝗱 𝗳𝗿𝗲𝗲𝗱 𝘂𝗽 𝟭,𝟬𝟭𝟱 𝗳𝘂𝗹𝗹-𝘁𝗶𝗺𝗲 𝗰𝗮𝗿𝗲 𝘄𝗼𝗿𝗸𝗲𝗿𝘀' 𝘄𝗼𝗿𝘁𝗵 𝗼𝗳 𝗰𝗮𝗽𝗮𝗰𝗶𝘁𝘆, 𝘄𝗶𝘁𝗵 𝗲𝘃𝗲𝗿𝘆 𝗻𝘂𝗺𝗯𝗲𝗿 𝘀𝘂𝗯𝘀𝘁𝗮𝗻𝘁𝗶𝗮𝘁𝗲𝗱.

Scroll down for the full report, for questions, just send Douwe Jippes, Alexander van der Wyck, Karen Berg or Thom Nefkens a personal message.

Not promises. Proof. 💪

‍